VDAC2

Across TCGA pan-cancer cohorts, VDAC2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated VDAC2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher VDAC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VDAC2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where VDAC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.711	0.969	<.001	82	view →
HNSC	OS	Median	II,III,IV	0.948	0.754	<.001	81	view →
LUAD	DFS	Median	II,III,IV	0.209	0.764	.001	36	view →
LSCC	OS	Median	All	1.000	0.936	.010	14	view →
COAD	DFS	Tertile	IV	0.432	0.944	.038	12	view →
PDAC	DFS	Median	II,III,IV	0.319	0.504	.039	4	view →
GBM	DFS	Quartile	All	0.919	0.677	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

VDAC2–CCRCC (OS)

Open the CCRCC breakdown →